Actilyse
ApprovedSmall molecule
Boehringer IngelheimActilyse is one of 138 small molecule programs targeting Stroke. It is currently in Approved.
5
Indications
8
Total Trials
0
Active Trials
137
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
461 competitors in Stroke
#DrugCompanyPhaseTrials
1Actilyse
Boehringer IngelheimApproved
Activase
RochePreclinical
Folvite
Eli LillyPreclinical
Proamatine
TakedaPreclinical
Repatha
AmgenPreclinical
Botox
RRevance Therapeutics, Inc.
Preclinical
Periactin
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Zantac 150
CChattem
Preclinical
Alka-Seltzer
AAbbott
Preclinical
Anticoagulant
BayerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Stroke2 trials
New Acute Treatment for Stroke - The Effect of Remote PERconditioning
Completed·—·Phase 3·NCT00975962·120 enrolled
Intracranial Collaterals in Acute Stroke and Clinical Outcome
Completed·—··NCT03311386·40 enrolled
Myocardial Infarction1 trial
Pulmonary Embolism1 trial
Efficacy and Safety1 trial
Cerebral Infarction1 trial
Which Factors Influence the Duration and the Success of Mechanical Thrombectomy During the Acute Phase of Cerebral Infarction?
Completed·—··NCT03451903·106 enrolled
2 more indications
Ischemic stroke1 trial
Anxiety and Depression Disorder in Patient Treated With rTPA for Mangment of Acute Ischemic Stroke
Unknown status·—··NCT04484558·40 enrolled
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Actilyse. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company